Industries › Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing
NAICS 3254Industry group0.1% of all approvals
SBA loans for pharmaceutical and medicine manufacturing
7(a) and 504 approvals to businesses SBA classifies under NAICS 3254, with the lenders and states behind them.
SBA approvals by fiscal year. The federal fiscal year runs 1 October to 30 September, so FY2025 is 1 October 2024 to 30 September 2025. *FY2026 is open: approvals to 30 Jun 2026 only.
Businesses classified under NAICS 3254, pharmaceutical and medicine manufacturing, received 216 SBA loan approvals worth $268M in FY2021 to FY2025 (185 7(a), 31 504).
That is 0.1% of all approvals. Set against the 2,905 establishments the Census Bureau counts in the industry, it comes to 74.4 approvals per 1,000 establishments; across all industries the figure is 41.0.
In FY2025 there were 61 approvals, up 74% on FY2024. The median 7(a) approval was $500K, against $190K for all industries.
Of 7(a) loans approved in FY2010 to FY2021 and disbursed, SBA records 4.9% as charged off, below the 6.6% for all industries.
Loan status is as recorded by SBA at the data date; charge-off rates are computed on loans approved at least five fiscal years ago. Jobs supported are self-reported estimates from the SBA loan application, which SBA does not review, audit or validate. Data through 30 Jun 2026.
Volume by fiscal year
| Fiscal year | 7(a) approvals | 7(a) dollars | Median 7(a) | 504 approvals | 504 dollars | All approvals | Jobs supported, as reported |
|---|---|---|---|---|---|---|---|
| FY2026* | 20 | $16.4M | $313K | 5 | $16.3M | 25 | 369 |
| FY2025 | 55 | $47.5M | $400K | 6 | $24.8M | 61 | 696 |
| FY2024 | 30 | $34.1M | $487K | 5 | $9.1M | 35 | 626 |
| FY2023 | 31 | $41.2M | $500K | 3 | $3.2M | 34 | 739 |
| FY2022 | 26 | $19.9M | $244K | 6 | $8.3M | 32 | 495 |
| FY2021 | 43 | $57.7M | $1.0M | 11 | $22.3M | 54 | 1,056 |
| FY2020 | 27 | $20.7M | $350K | 7 | $16.4M | 34 | 400 |
| FY2019 | 26 | $30.0M | $454K | 4 | $2.7M | 30 | 475 |
| FY2018 | 32 | $27.5M | $305K | 5 | $7.7M | 37 | 449 |
| FY2017 | 30 | $21.7M | $375K | 8 | $10.7M | 38 | 698 |
| FY2016 | 34 | $33.4M | $324K | 5 | $7.8M | 39 | 1,104 |
SBA records the NAICS code in force when a loan was approved. The 2022 NAICS revision renumbered parts of retail trade and information, so some lines of business appear under one code before FY2023 and another after. FY2016–FY2020 approvals under this code: 178.
Lenders most active in this industry
By number of approvals, FY2021–FY2025; 99 lenders had at least one.
| # | Lender | Approvals | Dollars | Share | |
|---|---|---|---|---|---|
| 1 | Newtek Bank, National AssociationMiami, FL | 12 | $12.6M | 5.6% | |
| 2 | TD Bank, National AssociationWilmington, DE | 9 | $1.9M | 4.2% | |
| 3 | Manufacturers and Traders Trust CompanyBuffalo, NY | 8 | $1.2M | 3.7% | |
| 4 | Northeast BankLewiston, ME | 7 | $2.2M | 3.2% | |
| 5 | Firstrust Savings BankConshohocken, PA | 6 | $5.9M | 2.8% | |
| 6 | Readycap Lending, LLCBerkeley Heights, NJ | 6 | $1.9M | 2.8% | |
| 7 | Celtic Bank CorporationSalt Lake City, UT | 5 | $4.3M | 2.3% | |
| 8 | BayFirst National BankSaint Petersburg, FL | 5 | $1.5M | 2.3% | |
| 9 | The Huntington National BankColumbus, OH | 5 | $1.5M | 2.3% | |
| 10 | CDC Small Business Finance Corp.San Diego, CA | 5 | $1.1M | 2.3% | |
| 11 | Eastern BankBoston, MA | 5 | $1.1M | 2.3% | |
| 12 | Provident BankJersey City, NJ | 4 | $5.4M | 1.9% | |
| 13 | Newtek Small Business Finance, Inc.Lake Success, NY | 4 | $4.7M | 1.9% | |
| 14 | Central BankProvo, UT | 4 | $4.6M | 1.9% | |
| 15 | Choice Financial GroupFargo, ND | 4 | $3.5M | 1.9% | |
| 16 | Peapack Private Bank and TrustBedminster, NJ | 3 | $8.7M | 1.4% | |
| 17 | InBankRaton, NM | 3 | $8.1M | 1.4% | |
| 18 | First Internet Bank of IndianaFishers, IN | 3 | $7.5M | 1.4% | |
| 19 | Mountain West Small Business FinanceSalt Lake City, UT · CDC | 3 | $6.5M | 1.4% | |
| 20 | Live Oak Banking CompanyWilmington, NC | 3 | $5.9M | 1.4% |
States
| # | State of the business | Approvals | Dollars | Share | |
|---|---|---|---|---|---|
| 1 | California | 28 | $40.7M | 13.0% | |
| 2 | Florida | 25 | $36.3M | 11.6% | |
| 3 | New Jersey | 20 | $27.5M | 9.3% | |
| 4 | Texas | 15 | $31.9M | 6.9% | |
| 5 | Utah | 14 | $17.7M | 6.5% | |
| 6 | Pennsylvania | 13 | $15.4M | 6.0% | |
| 7 | Massachusetts | 13 | $4.9M | 6.0% | |
| 8 | New York | 12 | $16.6M | 5.6% | |
| 9 | Washington | 8 | $8.2M | 3.7% | |
| 10 | Minnesota | 6 | $5.0M | 2.8% | |
| 11 | Oklahoma | 5 | $6.4M | 2.3% | |
| 12 | Nebraska | 4 | $4.9M | 1.9% | |
| 13 | Oregon | 4 | $3.1M | 1.9% | |
| 14 | Maryland | 4 | $2.1M | 1.9% | |
| 15 | Iowa | 3 | $8.8M | 1.4% |
Franchise brands
0.9% of approvals carried a franchise code.
| # | Brand | Approvals | Share | |
|---|---|---|---|---|
| 1 | Vital Care | 2 | 0.9% |
Approval sizes
- $50,000 or less8.3%18
- $50,001 to $150,00014.4%31
- $150,001 to $350,00015.3%33
- $350,001 to $1 million25.9%56
- $1 million to $2 million13.0%28
- Over $2 million23.1%50
Age of the businesses
- Existing, more than 2 years old76.4%165
- New business, 2 years or less13.0%28
- Startup, loan funds will open the business6.0%13
- Change of ownership4.6%10
Charge-offs against all industries
| Loans approved FY2010–FY2021 | This industry, 7(a) | All 7(a) | This industry, 504 | All 504 |
|---|---|---|---|---|
| Approvals in these years | 373 | 639,905 | 86 | 85,591 |
| Cancelled or never disbursed | 48 | 79,313 | 17 | 12,514 |
| Disbursed loans | 325 | 560,592 | 69 | 73,077 |
| Paid in full | 255 | 435,813 | 38 | 35,491 |
| Charged off | 16 | 36,891 | 3 | 905 |
| Still outstanding (status exempt from disclosure) | 54 | 87,888 | 28 | 36,681 |
| Charged off, share of disbursed loans | 4.9% | 6.6% | 4.3% | 1.2% |
| Dollars charged off, share of disbursed dollars | 1.7% | 2.5% | 1.3% | 0.9% |
| Dollars charged off | $4.2M | $5.70bn | $1.3M | $499M |
Against all industries
| FY2021–FY2025 | NAICS 3254 | All industries |
|---|---|---|
| Median 7(a) approval | $500K | $190K |
| Median 504 approval | $1.4M | $657K |
| Average approval | $1.2M | $573K |
| Approvals per 1,000 establishments | 74.4 | 41.0 |
| Approvals to franchise businesses | 0.9% | 11.2% |
| Jobs supported per approval, as reported | 16.7 | 10.5 |
Questions and answers
Which lenders make the most SBA loans for pharmaceutical and medicine manufacturing?
By approvals in FY2021 to FY2025: Newtek Bank, National Association (12), TD Bank, National Association (9), Manufacturers and Traders Trust Company (8), Northeast Bank (7), Firstrust Savings Bank (6). 99 lenders had at least one.
How large are typical SBA loans for pharmaceutical and medicine manufacturing?
The median 7(a) approval was $500K and the median 504 approval $1.4M; the average across both programs was $1.2M.
What share of SBA loans for pharmaceutical and medicine manufacturing are charged off?
Of 7(a) loans approved in FY2010 to FY2021 and disbursed, 4.9% are recorded as charged off, against 6.6% for all industries; for 504 loans, 4.3% against 1.2%.
Which states have the most SBA loans for pharmaceutical and medicine manufacturing?
California (28), Florida (25), New Jersey (20), Texas (15), Utah (14).
Is SBA lending for pharmaceutical and medicine manufacturing rising?
Approvals in the three latest complete fiscal years total 130, against 120 in the three before: broadly level (+8%).
About these figures
Figures are totals of the Small Business Administration's 7(a) and 504 FOIA loan files, data through 30 Jun 2026. SBA updates the files quarterly. Counts are loan approvals, including approvals later cancelled; the five-year window is FY2021–FY2025, the five latest complete fiscal years. Charge-off rates use only loans approved in FY2010–FY2021, at least five fiscal years ago, and count disbursed loans SBA records as charged off. Loans are listed under the lender they are assigned to today. Establishment counts are from the Census Bureau's County Business Patterns 2023, which leaves out most farms, government and businesses without employees. Dollar figures behind fewer than three approvals are not shown, and no borrower is named anywhere on this site.Methodology · Report an error